Supported Isolation Facilities
Hospital or Outpatient Clinic medical professionals, or their designees (discharge planners), seeking to discharge or transfer patients in need of a place to complete their isolation, should attach their patient’s History and Physical Note (Hospital) or Visit Note (Outpatient Clinic) to the online central intake form. Please complete the entire form; leaving any field blank will delay the referral review process.
Carefully investigate and communicate, within the form, any high-risk medical or psychiatric conditions, security concerns, criminal history, or need for any wrap-around support services.
This information is essential to ensure the patient is routed to the appropriate isolation facility.
Please contact CoronavirusSocialWork@cityofchicago.org, between the hours of 8:00 am to 6:00pm, if you have any questions or concerns, or have not received a referral response within 4 hours of form submission.
- Patient must have laboratory-confirmed COVID-19 diagnosis, and
- cannot safely return to or isolate in their place of residence
- be able to perform most activities of daily living (ADLs)
- Signs or symptoms of severe COVID-19 disease: e.g. temperature >103°F; Oxygen saturation <92% on room air; respiratory rate of >30 breaths per minute; difficulty breathing/respiratory distress.
- Use of supplemental oxygen to maintain O2 saturation above 92% (there may be some limited capacity to manage patients on <1L of O2, considered on an individual basis)
- Blood glucose readings >300 mg/dL
- Uncontrolled and symptomatic hypertension
- Pregnancy beyond 20.0 weeks gestational age
- Receiving hemodialysis (might be accommodated if the transfer has an established relationship with a dialysis facility).
- Alcohol withdrawal risk (history of alcohol use disorder or alcohol dependence and recent last drink)
- Opioid withdrawal AND disinterest in medications for opioid use disorder (MOUD)/medication assisted therapy (MAT)
- Severe uncontrolled psychosis (patients currently taking antipsychotic medications and stable are NOT excluded)
- Active suicidal/homicidal ideation
- Diagnosis of acute tuberculosis
- Acute diarrheal illness, active XDRO, Candida auris colonization or infection
- Current infestations such as scabies, bedbugs, or scabies; (clients who completed treatment are not excluded)
- Personality disorders that challenge the person’s ability to abide by facility rules
Unwillingness or inability to stay at the isolation facility through completion of the isolation period
- 10 days or more from symptom onset; AND 3 days (72 hours) or more afebrile without antipyretics and improved symptoms, whichever is longer.
- Cleared for discharge by healthcare provider on site.
Notes on Completing the Minimum Isolation Period
After the minimum isolation period has been completed, clients may return to a general congregate facility.
CDPH recommends following CDC recommendations for preventing community transmission COVID-19 disease: https://www.cdc.gov/coronavirus/2019-ncov/community/homeless-shelters/plan-prepare-respond.html.
Individual facilities may choose to maintain transitional precautions beyond the minimum isolation period based on the ability to maintain adequate social distancing and hygiene as recommended for all clients during current widespread COVID-19 community transmission. Additional measures could include the following:
- Continue to implement social distancing measures and encourage recovering clients to wear a cloth face covering in common areas where social distancing is challenging until all symptoms are completely resolved or until 14 days after illness onset, whichever is longer.
- Continue to keep beds at least 6 feet apart, use temporary barriers between beds (such as curtains), and request that all clients sleep head-to-toe.
Consultation is available for individual cases, but in general, clients should not be prevented from returning to the referring facility if they have completed the minimum isolation period described above which is intended to minimize risk of transmission for a range of disease severity associated with COVID-19.